Chemistry:Siramesine

From HandWiki
Short description: Chemical compound
Siramesine
Siramesine1.svg
Siramesine 3D BS.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC30H31FN2O
Molar mass454.589 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Siramesine (or Lu 28-179) is a sigma receptor agonist, selective for the σ2 subtype.[1] In animal studies, siramesine has been shown to produce anxiolytic[2] and antidepressant[3] effects. It was developed by the pharmaceutical company H Lundbeck for the treatment of anxiety,[4] although development was discontinued after clinical trials showed a lack of efficacy in humans. Siramesine has been shown to produce an enhanced antidepressant effect when co-administered with NMDA antagonists.[5] It has also been used to study the σ2 activity of cocaine,[6] and has been shown to produce anticancer properties both in vitro[7] and in vivo.[8]

References

  1. "Lu 28-179 labels a sigma(2)-site in rat and human brain". Neuropharmacology 43 (1): 95–100. July 2002. doi:10.1016/s0028-3908(02)00071-0. PMID 12213263. 
  2. "The selective sigma2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents". The Journal of Pharmacology and Experimental Therapeutics 283 (3): 1323–32. December 1997. PMID 9400007. 
  3. "The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression". Behavioural Pharmacology 11 (2): 117–24. April 2000. doi:10.1097/00008877-200004000-00003. PMID 10877116. 
  4. "Siramesine H Lundbeck". Current Opinion in Investigational Drugs 2 (2): 266–70. February 2001. PMID 11816842. 
  5. "The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats.". Journal of Physiology and Pharmacology 57 (2): 217–29. June 2006. PMID 16845227. http://jpp.krakow.pl/journal/archive/06_06/pdf/217_06_06_article.pdf. 
  6. "Sigma2 (sigma2) receptors as a target for cocaine action in the rat striatum". European Journal of Pharmacology 535 (1–3): 98–103. March 2006. doi:10.1016/j.ejphar.2005.12.077. PMID 16480713. 
  7. "Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress". Cancer Research 65 (19): 8975–83. October 2005. doi:10.1158/0008-5472.CAN-05-0269. PMID 16204071. 
  8. "Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine". Cancer Research 67 (5): 2217–25. March 2007. doi:10.1158/0008-5472.CAN-06-3520. PMID 17332352. 

External links